ME
Medico Remedies Ltd (MEDICO)
₹21.99
Mkt cap
₹290 Cr
P/E ratio
21.00
P/B
2.42
Div yield
0.00%
ROE
19.00%
ROCE
23.30%
EPS (TTM)
₹1.05
Book value
₹9
52W range
20–57
Sector
Healthcare
Price history
Previous close
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations [1]
NSE MEDICOBSE 540937
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−61.34% from high₹22
₹20+7.43% from low₹57
Current
₹21.99
Prev close
₹21.62
Day
+1.71%
Price performance
1D
+1.71%
1W
−1.39%
1M
−44.33%
3M
−44.68%
6M
−41.84%
1Y
−54.45%
YTD
−56.34%
Financials
Revenue, profit & margin
P/E ratio
21.0×
MEDICO is 39% below the sector median of 34.6×
MEDICO21.0×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 31.47 | 42.36 | 29.77 | 41.32 | 30.80 | 39.35 | 39.49 | 41.30 | 38.25 | 52.64 | 58.68 | 56.81 | 69.40 | |
| Expenses | 29.01 | 39.29 | 27.04 | 36.67 | 27.98 | 36.94 | 36.38 | 34.64 | 35.43 | 49.91 | 54.35 | 49.66 | 66.10 | |
| Operating Profit | 2.46 | 3.07 | 2.73 | 4.65 | 2.82 | 2.41 | 3.11 | 6.66 | 2.82 | 2.73 | 4.33 | 7.15 | 3.30 | |
| OPM % | 7.82% | 7.25% | 9.17% | 11.25% | 9.16% | 6.12% | 7.88% | 16.13% | 7.37% | 5.19% | 7.38% | 12.59% | 4.76% | |
| Other Income | 0.31 | 0.96 | 0.27 | 0.58 | 0.29 | 0.68 | 1.43 | 0.29 | 0.66 | 1.72 | 0.68 | 2.87 | 1.17 | |
| Interest | 0.17 | 0.18 | 0.22 | 0.25 | 0.18 | 0.21 | 0.28 | 0.49 | 0.28 | 0.24 | 0.39 | 0.90 | 0.41 | |
| Depreciation | 0.71 | 0.71 | 0.72 | 0.74 | 0.75 | 0.75 | 0.76 | 0.77 | 0.77 | 0.73 | 0.79 | 0.80 | 0.72 | |
| Profit before tax | 1.89 | 3.14 | 2.06 | 4.24 | 2.18 | 2.13 | 3.50 | 5.69 | 2.43 | 3.48 | 3.83 | 8.32 | 3.34 | |
| Tax % | 29.63% | 22.61% | 30.10% | 26.89% | 27.06% | 27.23% | 25.14% | 23.90% | 25.51% | 25.86% | 25.07% | 29.69% | 24.55% | |
| Net Profit | 1.32 | 2.43 | 1.45 | 3.10 | 1.58 | 1.55 | 2.62 | 4.34 | 1.82 | 2.57 | 2.87 | 5.86 | 2.52 | |
| EPS in Rs | 0.16 | 0.29 | 0.17 | 0.37 | 0.19 | 0.19 | 0.32 | 0.52 | 0.22 | 0.31 | 0.35 | 0.71 | 0.30 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −4.76% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 13 Aug '26◦ |
| Earnings day | −4.76% |
| +1 day | −7.50% |
| +5 days | −10.89% |
| +15 days | −16.69% |
| +30 days | −53.41% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202661.38%Promoter
Promoters61.38%
FIIs0.08%0.05
DIIs0.00%
Public38.55%0.05
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Medico Remedies | ₹34.89 | 20.95 | 290 | 0.00% | 3 | +38.46% | 69 | +81.44% | 23.27% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports9
Concall transcripts2
Credit ratings4
Announcements5
Reg. 34 (1) Annual Report. 29 Aug - Annual Report FY2025-26 and AGM notice; meeting on 22 September 2026, with director reappointments and remuneration changes.Intimation Of Book Closure Date Pursuant To Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015. 29 AugSubmission Of Annual Report For The Financial Year 2025-26 Along With The Notice Of The 32Nd Annual General Meeting 29 AugClarification On Price Movement 17 Aug - Company says share price movement is market-driven; no pending disclosures.Financial Results For The Quarter Ended On 30Th June, 2026 13 Aug - Board approved Q1 FY27 results, reappointed two WTDs, raised MD remuneration, and issued 32nd AGM notice.